- Home
- MGLD vs RNTX Comparison
MGLD vs RNTX Comparison
Compare MGLD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- RNTX
- Stock Information
- Founded
- MGLD 1996
- RNTX 2001
- Country
- MGLD United States
- RNTX United States
- Employees
- MGLD N/A
- RNTX N/A
- Industry
- MGLD Finance/Investors Services
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- RNTX Health Care
- Exchange
- MGLD Nasdaq
- RNTX Nasdaq
- Market Cap
- MGLD 35.8M
- RNTX 40.3M
- IPO Year
- MGLD N/A
- RNTX N/A
- Fundamental
- Price
- MGLD $0.82
- RNTX $1.45
- Analyst Decision
- MGLD
- RNTX
- Analyst Count
- MGLD 0
- RNTX 0
- Target Price
- MGLD N/A
- RNTX N/A
- AVG Volume (30 Days)
- MGLD 17.1K
- RNTX 37.5K
- Earning Date
- MGLD 05-08-2025
- RNTX 08-13-2025
- Dividend Yield
- MGLD N/A
- RNTX N/A
- EPS Growth
- MGLD N/A
- RNTX N/A
- EPS
- MGLD N/A
- RNTX N/A
- Revenue
- MGLD $31,205,000.00
- RNTX N/A
- Revenue This Year
- MGLD N/A
- RNTX N/A
- Revenue Next Year
- MGLD N/A
- RNTX N/A
- P/E Ratio
- MGLD N/A
- RNTX N/A
- Revenue Growth
- MGLD N/A
- RNTX N/A
- 52 Week Low
- MGLD $0.70
- RNTX $1.33
- 52 Week High
- MGLD $2.10
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- MGLD 46.87
- RNTX N/A
- Support Level
- MGLD $0.77
- RNTX N/A
- Resistance Level
- MGLD $0.82
- RNTX N/A
- Average True Range (ATR)
- MGLD 0.07
- RNTX 0.00
- MACD
- MGLD -0.01
- RNTX 0.00
- Stochastic Oscillator
- MGLD 18.64
- RNTX 0.00
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.